American Century Companies Inc. Has $26.85 Million Stake in Jazz Pharmaceuticals PLC $JAZZ

American Century Companies Inc. lifted its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 34.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 253,030 shares of the specialty pharmaceutical company’s stock after acquiring an additional 64,968 shares during the quarter. American Century Companies Inc. owned approximately 0.42% of Jazz Pharmaceuticals worth $26,852,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in JAZZ. Rhumbline Advisers boosted its position in Jazz Pharmaceuticals by 0.3% during the second quarter. Rhumbline Advisers now owns 165,012 shares of the specialty pharmaceutical company’s stock worth $17,511,000 after purchasing an additional 456 shares during the period. Legal & General Group Plc lifted its stake in shares of Jazz Pharmaceuticals by 11.2% during the 2nd quarter. Legal & General Group Plc now owns 185,824 shares of the specialty pharmaceutical company’s stock worth $19,720,000 after buying an additional 18,675 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Jazz Pharmaceuticals by 3.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,721,294 shares of the specialty pharmaceutical company’s stock worth $182,664,000 after buying an additional 59,252 shares during the last quarter. Ensign Peak Advisors Inc boosted its holdings in shares of Jazz Pharmaceuticals by 17.9% during the 2nd quarter. Ensign Peak Advisors Inc now owns 28,435 shares of the specialty pharmaceutical company’s stock worth $3,018,000 after buying an additional 4,316 shares during the period. Finally, EMC Capital Management acquired a new position in Jazz Pharmaceuticals in the 2nd quarter valued at about $344,000. Institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Heather Ann Mcsharry sold 3,415 shares of the stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $177.78, for a total transaction of $607,118.70. Following the sale, the director directly owned 20,449 shares in the company, valued at $3,635,423.22. This represents a 14.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Rick E. Winningham sold 5,500 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $180.86, for a total transaction of $994,730.00. Following the completion of the transaction, the director directly owned 8,893 shares in the company, valued at approximately $1,608,387.98. This represents a 38.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 50,893 shares of company stock valued at $8,559,699 over the last three months. 4.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

JAZZ has been the subject of several research reports. Truist Financial raised their price objective on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a research report on Thursday, August 28th. Bank of America increased their target price on Jazz Pharmaceuticals from $230.00 to $247.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Wall Street Zen raised Jazz Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, August 28th. Finally, UBS Group reiterated a “neutral” rating and set a $188.00 price objective (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Monday, November 24th. Thirteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $195.67.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $176.61 on Monday. The firm has a market cap of $10.73 billion, a PE ratio of -26.24, a price-to-earnings-growth ratio of 8.49 and a beta of 0.29. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37. The stock’s fifty day moving average price is $143.87 and its two-hundred day moving average price is $125.27. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $182.99.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.